Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
- Resource Type
- Authors
- Winston Lee; Mark P. Breazzano; Stephen H. Tsang; Suzanne Daly; Janet R. Sparrow; D. Jackson Coleman
- Source
- American Journal of Ophthalmology Case Reports
American Journal of Ophthalmology Case Reports, Vol 21, Iss, Pp 100998-(2021)
- Subject
- medicine.medical_specialty
business.industry
Sildenafil
Central serous chorioretinopathy
Urology
Case Report
Phosphodiesterase inhibition
respiratory tract diseases
Ophthalmology
chemistry.chemical_compound
Serous fluid
lcsh:Ophthalmology
chemistry
lcsh:RE1-994
cardiovascular system
Medicine
business
PDE5/6 inhibitor
Dechallenge
- Language
- English
- ISSN
- 2451-9936
Purpose Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). Observations In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy. Conclusions AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.